Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glioblastoma multiforme

Glioblastoma multiforme

Part of Glioma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glioblastoma multiforme

60 trials tracked for Glioblastoma multiforme: 1 in phase 3 or 4.

60Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 52 Phase 1 4 Other / NA 3
  1. Phase 3 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed
  2. Phase 2 Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma Completed
  3. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  4. Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme Completed
  5. Phase 2 Temozolomide Chronotherapy for High Grade Glioma Completed
  6. Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme Completed
Show 44 more trials
  1. Phase 2 FET-PET for Evaluation of Response of Recurrent GBM to Avastin Completed
  2. Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed
  3. Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
  4. Phase 2 Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme Completed
  5. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  6. Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed
  7. Phase 2 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) Completed
  8. Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Completed
  9. Phase 2 Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed
  10. Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Completed
  11. Phase 2 Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Completed
  12. Phase 2 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas Completed
  13. Phase 2 Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma Completed
  14. Phase 2 A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma Completed
  15. Phase 2 Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma Completed
  16. Phase 2 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
  17. Phase 2 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM Completed
  18. Phase 2 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed
  19. Phase 2 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Completed
  20. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  21. Phase 2 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed
  22. Phase 2 Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Completed
  23. Phase 2 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Completed
  24. Phase 2 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma Completed
  25. Phase 2 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed
  26. Phase 2 Amgen 386 for Recurrent Glioblastoma Completed
  27. Phase 2 DC Migration Study for Newly-Diagnosed GBM Completed
  28. Phase 2 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme Completed
  29. Phase 2 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme Completed
  30. Phase 2 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Completed
  31. Phase 2 Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme Completed
  32. Phase 2 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Completed
  33. Phase 2 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Completed
  34. Phase 2 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Completed
  35. Phase 2 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed
  36. Phase 2 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme Completed
  37. Phase 2 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Completed
  38. Phase 2 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Completed
  39. Phase 2 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme Completed
  40. Phase 2 Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma Completed
  41. Phase 2 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Completed
  42. Phase 2 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma Completed
  43. Phase 2 Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma Completed
  44. Phase 2 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Oncology Meta-analysis
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
May 1, 2026
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme
Oncology Cohort
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme A Simple Brain Tumor Test Could Predict Your Treatment Path
This prospective observational cohort study evaluated PINK1 expression in adults (18+ years) with newly diagnosed IDH-wild type glioblastoma…
A specific protein in glioblastoma tissue could forecast survival odds, helping patients plan care even though the test is not available yet…
medRxiv Apr 10, 2026

Research across Glioma

Related studies from across the Glioma family.

Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
Allergy & Immunology Sys. Review
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
Frontiers Jun 15, 2026
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma
Allergy & Immunology Sys. Review
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma Single-cell atlas reveals how glioblastoma disables immune cells
This systematic review examines the immunological landscape of glioblastoma, specifically focusing on cytotoxic lymphocyte dysfunction. The …
A systematic review maps the cellular and molecular mechanisms behind immune failure in glioblastoma, identifying key targets for future the…
Frontiers Jun 10, 2026
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients
Oncology Meta-analysis
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients High blood cell ratios linked to shorter life in glioblastoma patients
This meta-analysis reviews data from 2609 patients with WHO grade 4 diffuse astrocytoma to evaluate platelet indices. High platelet: lymphoc…
High blood cell ratios are linked to shorter life in glioblastoma patients. This analysis of over 5,000 adults shows how simple blood tests …
May 23, 2026
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
Pulmonology & Critical Care Sys. Review
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Frontiers May 16, 2026
Review of glioma organoid models for mechanistic discovery and therapy development
Oncology Sys. Review
Review of glioma organoid models for mechanistic discovery and therapy development Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Frontiers May 15, 2026
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis
Rheumatology Meta-analysis
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis Brain Cancer Survival Jumps When Adding This Therapy to Chemo
A systematic review and meta-analysis of 2,376 patients found that adding tumor treating fields to chemotherapy significantly prolonged prog…
Adding a wearable electric field device to standard chemotherapy helps glioblastoma patients live significantly longer with similar major si…
Frontiers May 8, 2026
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
Oncology Sys. Review
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Frontiers May 5, 2026
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma Ultrasound Opens a New Door for Brain Cancer Treatment
This systematic review and meta-analysis evaluated focused ultrasound mediated gene therapy in preclinical orthotopic glioblastoma in vivo m…
A new review of nine studies shows that focused ultrasound can safely deliver gene therapy across the brain's protective barrier, shrinking …
May 4, 2026
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026
Specialized palliative care intervention enrollment patterns in a glioblastoma randomized controlled trial sub-analysis
Oncology RCT
Specialized palliative care intervention enrollment patterns in a glioblastoma randomized controlled trial sub-analysis Glioblastoma trial reveals why patients skip or delay visits
This sub-analysis of the Early Palliative Care for Patients with Glioblastoma (EPCOG) trial examined enrollment and retention among 556 scre…
Many glioblastoma patients skip or delay study visits due to illness or lack of interest, a new trial analysis finds.
Apr 27, 2026
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results
Oncology Phase I
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results New drug combo may help brain cancer patients who have run out of options
This Phase 1a trial in 63 patients (16 with glioblastoma) found LP-184 was well tolerated but with more transaminitis and thrombocytopenia i…
A new drug combination could help brain cancer patients by making their current medicine work much harder inside the tumor.
medRxiv Apr 25, 2026
Meta-analysis of TKI combinations in glioblastoma shows improved PFS and ORR with mixed safety signals
Oncology Meta-analysis
Meta-analysis of TKI combinations in glioblastoma shows improved PFS and ORR with mixed safety signals New Hope for Glioblastoma Patients Emerges
This meta-analysis evaluated combination treatments incorporating tyrosine kinase inhibitors (TKIs) versus TKI-free control regimens in 1,43…
Imagine getting the hardest diagnosis a person can hear: a fast-growing brain tumor with few good treatment options.
Frontiers Apr 23, 2026